Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.42 |
| ▸ | CASP6 | P55212 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 2/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.37 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6562746 | 0.81 | TIMP3 (0.50) | CYP1A2AURKAAURKBNT5EALDH1A1 | |
| SCHEMBL27425328 | 0.80 | CASP6 (0.45) | CYP1A2NT5EALDH1A1HSD17B10CASP6 | |
| SCHEMBL27429737 | 0.79 | NT5E (0.50) | CYP1A2NT5EALDH1A1HSD17B10CASP6 | |
| SCHEMBL29706553 | 0.79 | AURKA (0.62) | CYP1A2AURKAAURKBNT5EALDH1A1 | |
| SCHEMBL10539390 | 0.79 | AURKA (0.62) | CYP1A2AURKAAURKBNT5EALDH1A1 | |
| SCHEMBL156092 | 0.79 | AURKA (0.62) | CYP1A2AURKAAURKBNT5EALDH1A1 | |
| SCHEMBL10539372 | 0.77 | AURKA (0.60) | CYP1A2AURKAAURKBNT5EALDH1A1 | |
| SCHEMBL445795 | 0.77 | AURKA (0.60) | CYP1A2AURKAAURKBNT5EALDH1A1 | |
| Aniline SCHEMBL10587235 | 0.77 | AURKA (0.57) | CYP1A2AURKAAURKBNT5EALDH1A1 | |
| SCHEMBL9768417 | 0.74 | APEX1 (0.45) | CYP1A2AURKAAURKBNT5EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228535-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2021-07-29 | — | — | US | disclosed |
| US-20210228535-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2021-07-29 | — | — | US | disclosed |
| US-10959979-B2 | Small molecules against cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2021-03-30 | — | — | US | disclosed |
| US-10959979-B2 | Small molecules against cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2021-03-30 | — | — | US | disclosed |
| US-20200268709-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2020-08-27 | — | — | US | disclosed |
| US-20200268709-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2020-08-27 | — | — | US | disclosed |
| US-10646465-B2 | Small molecules against cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2020-05-12 | — | — | US | disclosed |
| US-10646465-B2 | Small molecules against cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2020-05-12 | — | — | US | disclosed |
| US-20190240188-A1 | SMALL MOLECULES AGAINST CANCER | ALONBIO LTD. (IL) | 2019-08-08 | — | — | US | disclosed |
| US-20190240188-A1 | SMALL MOLECULES AGAINST CANCER | ALONBIO LTD. (IL) | 2019-08-08 | — | — | US | disclosed |
| WO-2017103931-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10959979-B2 | Small molecules against cancer | CCL2, CXCR2, CCL5 | CYP1A2 4419/4885AURKA 938/4885AURKB 287/4885 |
| US-20210228535-A1 | SMALL MOLECULES AGAINST CANCER | CCL2, CXCR2, CCL5 | CYP1A2 4419/4885AURKA 938/4885AURKB 287/4885 |
| US-10646465-B2 | Small molecules against cancer | CCL2, CXCR2, CCL5 | CYP1A2 4419/4885AURKA 938/4885AURKB 287/4885 |
| US-20200268709-A1 | SMALL MOLECULES AGAINST CANCER | CCL2, CXCR2, CCL5 | CYP1A2 4419/4885AURKA 938/4885AURKB 287/4885 |
| US-20190240188-A1 | SMALL MOLECULES AGAINST CANCER | CCL2, CXCR2, CCL5 | CYP1A2 4419/4885AURKA 938/4885AURKB 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.